If Novartis goes global with TPM voltaren the revenue would be greater than $5-6m.
I've heard varying degrees of voltaren gel sales with the lower end being around $300m-$500m globally.
A ready made market, I would suggest they might want to transition from the old to the new, but I would also expect a more effective gel will capture a percentage of the $500-$600m oral market.
So at even 3% we're looking at $9-$10m or 5% $15m-$20m +
Add that to your market cap!
eureka report, page-12
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
